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Background: Cognitions associated with craving and substance use are important contributors for the
psychological theories of Substance use disorders (SUD), as they may affect the course and treatment. In this study,
we aimed to validate Turkish version of two major scales ‘Beliefs About Substance Use’(BSU) and ‘Craving Beliefs
Questionnaire’(CBQ) in patients with heroin use disorder and define the interaction of these beliefs with patient
profile, depression and anxiety symptoms, with an aim to use these thoughts as targets for treatment.
Methods: One hundred seventy-six inpatients diagnosed with heroin use disorder and 120 participants in the
healthy comparison group were evaluated with CBQ, BSU, Beck Anxiety Inventory (BAI), Beck Depression Inventory
(BDI) and sociodemographic data questionnaire. Patient group was also evaluated with Addiction Profile Index.
Reliability and validity analysis for scales were conducted. Linear regression analysis was conducted to evaluate the
determinants of BSU and CBQ scores.
Results: Cronbach alpha level was 0.93 for BSU and 0.94 for CBQ. Patient group showed significantly higher CBQ,
BSU, BAI and BDI scores (p < 0.001). BSU score significantly correlated with API-substance use profile score, API-
diagnosis, BAI, BDI and CBQ (p < 0.005), whereas CBQ scores significantly correlated with API-diagnosis, API-impact
on life, API-craving, API-total score, BSU, BAI, BDI and amount of cigarette smoking (p < 0.002). Number of previous
treatments and age of onset for substance use were not correlated with either BSU or CBQ. BAI and BDI scores
significantly predicted BSU score, however only BDI score predicted CBQ score (p < 0.003).
Conclusions: Craving beliefs were highly correlated with addiction profile. Anxiety and depression are significant
modulators for patients’ beliefs about substance use and depression is a modulator for craving and maladaptive
beliefs, validating emotion-cognition interplay in addiction.
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Substance use disorders (SUD) are major public health
problems and a significant cost both for the individual
and the society [1]. Lifetime prevalence of substance use
is around 2.8% in Turkey. Of the patients who are ad-
mitted for treatment for the first time, 73% are reported
to be diagnosed with heroin use disorder and heroin is
the substance found to be most related with more than
half of drug induced deaths in young adults [2, 3] .One
of the latest reports point out that the prevalance of high
risk opioid use is in Turkey is around 0.03% and it is the
least reported rate among European countries, however
since 2009 both drug use and high risk opioid use have
dramatically increased in Turkey [3, 4].
Substance use disorders are results of a process, where
multiple factors take part both in the initiation and also in
the maintenance. With repeated use, substance use turns
into a chronic disorder, which is reinforced by both bio-
logical and psychological factors. Currently pharmacother-
apies are used to relieve the withdrawal symptoms and
also to decrease craving in the maintenance phase, with
limited efficacy [5, 6]. As a pharmacological approach,
opioid substitution treatment using buprenorphine-based
medication has been used in Turkey since 2010 Alcohol
and Drug Research, Treatment and Training Centre
(AMATEM) clinics [3]. On the other hand, cognitive and
behavioral approaches are also effective in the manage-
ment of opioid use disorders, by increasing the duration
of opioid abstinence days [7]. Current evidence shows that
pharmacological treatment is more effective when it is
used in combination with psychological treatments
than pharmacological or psychological treatments alone,
particularly for opiate users [8]. However, higher number
of studies that assess the effectiveness of either cognitive
behavioral therapy (CBT), the core beliefs and determi-
nants related with substance use are needed.
CBT of substance use disorders was suggested by
Aaron Beck et al., who had developed a theory about the
psychological origins of SUD and the interaction of
cognition or thought, emotion and behavior for this
disorder [9]. It is generally accepted that substance use
turns into a vicious cycle in patients diagnosed with
SUD. Even though withdrawal, craving or compulsive
use may decrease with pharmacotherapy, patients suffer
from their occupation with automatic thoughts, which
are easily triggered by conditional stimuli, emotional
states or any frustrating life event. Even experiencing
these automatic thoughts about SUD can be very stress-
ful for the individual and they may be overvalued as a
sign that they will not succeed in treatment of SUD.
CBT of SUD involves avoiding the high risk situations
and triggers of use, dealing with urge and craving, focus-
ing on automatic thoughts as beliefs about substance
and beliefs about craving [9, 10] and replacing them withmore adaptive alternative thoughts. Beck and Mitcheson
suggest that focusing on beliefs about substance is the
core to avoid the relapse [9, 11]. From the perspective of
cognitive behavioral therapy, these automatic thoughts
are also named as maladaptive thoughts since they are
inflexible, negatively biased, and negatively affecting the
course of the disorder [12] These beliefs may also influ-
ence not only the patients’ but also the treatment profes-
sionals and general public’s view about addiction [13].
Based on this observation, Beck et al. generated two
questionnaires: Beliefs about substance use (BSU) to
define substance addict’s beliefs about substance use and
rate beliefs statements and Craving Beliefs Questionnaire
(CBQ) to define the role of craving related automatic
thoughts. Both scales are Likert type and self-report
[14]. Originals of these questionnaires can be found in
A. Beck’s “Cognitive Therapy of Substance Use” book
[9]. Aslan S. et al [15] previously translated these scales
to Turkish for its use in patients diagnosed with alcohol
use disorder and it was found to be reliable.
Previous literature about craving beliefs suggests that
craving beliefs modify the course of methamphetamine
use [16]. But it is not known if craving beliefs affect the
course only in less dependent individuals as seen in
smokers [17] or if it is effective for people with severe
SUD as well. In addition, depressive disorders and anx-
iety disorders are known to lead to negative automatic
thoughts and decreased self confidence for problem
solving [18] however how these symptoms interact with
craving beliefs and beliefs about substance use is also
not studied as far as we know.
Opioids have an anxiolytic effect at the beginning, but
chronic opioid use causes depressive symptoms and
chronic anxiety. Moreover; negative mood, high level
distress intolerance are also associated with low treat-
ment incidence and increased relapses in substance
abusers [19, 20] Experiencing an anhedonic state may
play a role in the onset of addiction and reduce the cap-
acity of individuals to overcome the symptoms of early
stages of abstinence [21]. Heroin related cognitions have
important roles in the frequency of heroin use [22]. For
this reason, it is necessary to detect affective symptoms
and cognitive distortions that may affect addictive be-
havior in the assessment of the patients with SUD.
To our knowledge, BSU und CBQ are the only scales
that assess distorted thoughts specific to substance use.
These scales separate thoughts related with maintenance
of substance use into two categories and they give re-
searchers and clinicians a chance to find moderators of
different clinical courses.
Based on the aforementioned gap in the current litera-
ture and as clinicians working with patients diagnosed
with SUD and using CBT methods in their follow-up in-
terviews, we felt the need to reestablish the Turkish
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this aim, we tested the validity and the reliability of
Turkish version of BSU and CBQ in patients diagnosed
with heroin use disorder by comparing this group with
healthy individuals. As a second aim, we aimed to define
the effect of beliefs about substance use and craving
beliefs on the course of opioid addiction and to define the
modulatory role of depressive and anxious symptoms on
beliefs about substance use and craving beliefs, in order to
address the emotion-cognition interplay in SUD.
Method
Translation steps
Authors received permission from Guilford Press, the
original right holder of the scales, for the scales transla-
tion [23]. BSU and CBQ were translated to Turkish by
two authors. The translated scales were compared to
previously used Turkish scales in patients with alcohol
use disorder [15]. One author translated scales back to
English, and then a professional translator compared
them with the original versions. Inconsistencies were
corrected by consensus.
Participants
The study was performed at Alcohol and Drug Research,
Treatment and Training Centre (AMATEM) of Ankara
Numune Training and Research Hospital and Gazi
University Faculty of Medicine Department of Psychiatry
between September 2015 and February 2016. We tried
to recruit at least 5 subjects per item of the scales as
suggested by Gorsuch [24] and recruited all inpatients
that provided a written informed consent during the
study period. All participants were older than 18 years of
age. One hundred seventy-six non-alcoholic inpatients
diagnosed with heroin use disorder according to DSM-5
[25] criteria by a psychiatrist and 120 healthy volunteers
who had never used alcohol or any other substances,
and who did not have a psychiatric diagnosis, were
included in this study. Healthy comparison group has
been selected from hospital workers, relatives of the psy-
chiatric and other medical disorder outpatients and
volunteers who applied after advertising the study.
Patients with a comorbid diagnosis of mental retard-
ation, schizophrenia, bipolar disorder or dementia were
excluded. Study groups were matched for age, gender
and income level. The local ethics committee of Gazi
University Faculty of Medicine has approved this study
by IRB date and number: 09.05.2013/01.
Procedures and measurements
Patients and healthy comparison group were informed
about the purpose and procedures of the study and an
informed consent was obtained from every participant.
A sociodemographic data form to note the generalproperties of the sample was used to assess all patients
and healthy comparison group. For the patient group, all
scales were given to the patients at the second week of
treatment after completion of detoxification. It was reas-
sured that the patients were not in a withdrawal state or
actively craving for the substance. The following scales
were administered to both groups for reliability and val-
idity assessment and also to define the relationship of
depressive and anxious symptoms with beliefs about
substance use and craving beliefs.
Socio demographic data form was generated by the
authors to obtain general demographical data such as
age, gender, educational status, marital status, and occu-
pation and substance use disorder related variables. A
psychiatrist filled each form during the face-to-face
interview with participants. The questionnaire also
included questions to record the substance use profile of
the patients. For the patient group, age of substance use
onset and duration since the onset of first substance use,
names and durations of the used substances, the reason
of using substance, number of previous applications for
treatment, presence of physical and mental illness due to
the substance use, forensic events related to substance
use, substance use in family and neighborhood were also
questioned with a self prepared survey.
Craving beliefs questionnaire
CBQ is also a self-report questionnaire, where patients
rate their agreement with each 20 item on a 7 point
Likert scale. This questionnaire measures beliefs about
substance cravings [6, 10]. Higher scores indicate feeling
more helpless to deal with craving.
Beliefs about substance use questionnaire
The BSU is a self-report questionnaire, where patients
rate their agreement with each statement [14]. Turkish
version of the scale translated for patients with alcohol
use disorder, has shown to have good internal
consistency (Cronbach’s alpha 0.86) and reliability [15].
This 20 item, 7 point Likert scale involves items about
decreased self-efficacy and self-confidence to stop using
substance or to cheer up the life, in addition to
self-blaming thoughts.
Beck anxiety inventory (BAI) and Beck depression inventory
(BDI)
Symptoms of anxiety and depression were assessed by
BAI [26] and BDI [27], respectively. Both of these scales
consist of 21 multiple-choice questions and they are ac-
cepted as reliable and valid tools to assess anxious and de-
pressive symptoms. The Turkish version of both scales
were developed and psychometric properties were studied
[28].
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In order to obtain more data about substance use
disorder profile of the patients and to evaluate the
correlation of BSU and CBQ, API has also been applied
to SUD patient group. This scale has been developed by
K. Ögel [29]. It is a self-report questionnaire consisting
of 37 items and measuring a total score for addiction
and 5 subscales composed of (1) characteristics of
substance use; (2) diagnostic criteria of substance use
disorder; (3) the effects of substance use on the user; (4)
craving and (5) motivation to quit using substances. In
the first subscale, the number and frequency of used
alcohol/ substances and the problems created by them
are evaluated. Second subscale contains the diagnostic
criteria of substance use disorder according to DSM and
ICD. Third subscale includes questions that determine
the severity of addiction problems such as education,
work, family, economic, legal problems, pattern of sub-
stance use and criticism from the family or the environ-
ment. With the fourth subscale, it assesses craving of
substances. The last subscale evaluates the motivation to
stop the substance use. Thus, API allows measuring the
severity of different dimensions of substance use disorder.
Data analysis
SPSS statistical program package licensed to Koç
University has been used for all analysis. Groups were
compared for means of continuous variables using t-test
and for distribution of non-continuous variables using
chi-square or Fisher’s exact test. Factor analysis of CBQ
and BSU has been analyzed using Bartlett’s sphericity
test and Kaiser-Meyer-Olkin (KMO) test for sampling
adequacy. p < 0.05 was chosen as the significance level
for Bartlett’s sphericity test [30] and KMO scores
between 0 and 1 and factor analysis level of 0.6 was
chosen significant. According to Tabachnick and Fiddell,
threshold is .32 to decide type of rotation [31]. The Prin-
cipal Component Factor Analysis with Promax Rotation
was conducted to examine factorial structure of BSU
and CBQ. Cronbach alpha coefficient was calculated for
internal validity of BSU and CBQ.
Patient and healthy groups were compared for the
mean of continuous variables by t-test. Pearson correl-
ation analysis was conducted for the analysis of correl-
ation of BSU and CBQ scores. To test our second aim,
only patient group was analyzed separately for the
analysis of correlation of BSU or CBQ scores with age,
age of substance use onset, duration of substance use,
anxiety scores, depressive scores, API- total and subscale
scores and total cigarette smoking amount. A multivari-
ate linear regression analysis has been conducted to
define the predictors of BSU and CBQ scores. For the
analysis where smoking amount and age of onset for
substance use data were used, data of 169 heroin SUDpatients could be used due to missing data. p < 0.01 was
considered significant due to multiple comparisons.
Results
Sociodemographic variables table for age, gender,
educational level, income level
There were no significant differences between patients
and comparison group regarding mean age (23.8 ± 4.4
and 24.8 ± 4.7, respectively, p = 0.06, df: 294, t-test),
gender distribution (Male/female distribution: 169/7
and 118/2, p = 0.32, Fischer’s exact test), income level
(p = 0.17, Fischer’s exact test) and marital status (p = 0.2,
Fischer’s exact test). Educational level of the patients was
significantly lower than comparison group (p = 0.001,
Fischer’s exact test).
Validity for CBQ
We conducted factor analysis to examine the scale
characteristics of the data. Factor analysis showed that
the Kaiser-Meyer-Olkin measure of sampling adequacy
was .94 and that Bartlett’s test of Sphericity [32], which
assesses if the dataset is suitable for factor analysis, was
significant (p < 0.0001). As these tests were significant,
we interpreted the factor analysis results. Principal com-
ponents analysis with promax rotation conducted for
examining factor structure of CBQ with 20 items. It
extracted two factors with eigenvalues over 1 and
explained 58.4% of total variance (Table 1). Also, inspec-
tion of the screen-plot indicated two factors (Fig. 1). For
CBQ, we run 2 factors PCA followed by a promax rota-
tion again. The resulting correlation matrix for the fac-
tors shows that there are .66 correlations between factor
1 and 2.
As the assessment of discriminative validity, mean
CBQ scores of the healthy group (22.7±7.5) were signifi-
cantly lower than patients with substance use disorder
(64.3±25.5, p < 0.001).
Reliability for CBQ
Internal consistency: In order to determine the instru-
ment’s internal consistency reliability, the Cronbach
alpha coefficient was calculated. Its reliability was .94.
The internal consistency of CBQ subscales was .93 for
Subscale 1: Psychophysical reactions to craving, .88 for
Subscale 2: Weakness to cope with craving.
For subscale 1, intraclass correlation coefficient (ICC)
was used to determine the inter-rater reliability coeffi-
cient. It showed that there are strong reliability based
on the 95% confident interval of the ICC estimate
(ICC = 0.934, N = 295, P < 0.001). For subscale 2, intraclass
correlation coefficient (ICC) was used to determine the
inter-rater reliability coefficient. It showed there are strong
reliability based on the 95% confident interval of the ICC
estimate (ICC = 0.875, N = 295, P < 0.001).
Table 1 Items and Factor Loadings of CBQ
Item Factor loading
Factor 1: Psychophysical reactions to craving
CBQ10 Craving is my punishment for using prescription opioids 0.90
CBQ12 The images/ thoughts I have while craving prescription opioids are out of my control 0.88
CBQ2 If I don’t stop the cravings for prescription opioids, they will get worse 0.85
CBQ16 When I’m really craving prescription, I can not work. 0.84
CBQ13 The craving for prescription opioids make me so nervous I can’t stand it 0.82
CBQ11 If people have never used prescription opioids then they have no idea what craving really is. 0.81
CBQ4 The craving makes me use prescription opioids. 0.75
CBQ9 I can’t stand the physical symptoms I have while craving prescription opioids. 0.71
CBQ7 Once the craving for prescription opioids start, I have no control over my behavior. 0.65
CBQ3 Craving for prescription opioids can drive you crazy 0.64
CBQ1 Craving is a pyhsical reaction, I can not do anything about it 0.55
CBQ17 Either I’m craving prescription opioids or I ‘m not; there is nothing in between. 0.53
Factor 2: Weakness to cope with craving
CBQ15 Since I’ll have the craving the rest of my life I might as well go ahead and use prescription opioids 0.89
CBQ8 I’ll have cravings for prescription opioids the rest of my life 0.83
CBQ14 I’ll never be prepared to handle the craving for prescription opioids 0.77
CBQ19 When craving prescription opioids, it’s OK to use prescription opioids to use. 0.72
CBQ6 I don’t have any control over the craving for prescription opioids 0.70
CBQ20 The craving for prescription opioids are stronger than any my will power 0.63
CBQ5 I’ll always have cravings for prescription opioids 0.57
CBQ18 If the craving gets too intense, using prescription opioids is the only way to cope with the feeling. 0.46
Variance 58.3%
Component Number
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Fig. 1 Scree plot for CBQ
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as a primary criterion and must be equal to 0.30 or at
least greater than 0.25. For CBQ, the item discrimination
indices ranged from .49 to .80. The corrected item-total
correlations have shown that each of the items of CBQ
revealed good reliability (Table 2).Validity for BSU
Factor analysis showed that the Kaiser-Meyer-Olkin meas-
ure of sampling adequacy was .94 and Bartlett’s test of
Sphericity [32] was significant (p < 0.0001). Principal com-
ponents analysis with promax rotation conducted for
examining factor structure of BSU with 20 items. It
extracted two factors with eigenvalues over 1 and explained
54.5% of total variance (Table 3). For BSU, we run 2 factors
PCA followed by a promax rotation. The resulting correl-
ation matrix for the factors shows that there are .64 correla-
tions between factor 1 and 2. Also, inspection of the
screen-plot indicated two factors (Fig. 2). For BSU, we run
2 factors PCA followed by a promax rotation. The resulting
correlation matrix for the factors shows that there are .64
correlations between factor 1 and 2. As the assessment of
discriminative validity, we found a significant difference
among research groups based on t-test. BSU mean scores
of heroin SUD patients (54.05±24.5) were found to beTable 2 Item-total correlation and Cronbach’s alpha if item
deleted for CBQ
CBQ item Item-total correlation Cronbach’s Alpha if item deleted
CBQ1 0.59 0.94
CBQ2 0.77 0.93
CBQ3 0.73 0.93
CBQ4 0.80 0.93
CBQ5 0.62 0.94
CBQ6 0.58 0.94
CBQ7 0.72 0.94
CBQ8 0.61 0.94
CBQ9 0.56 0.94
CBQ10 0.69 0.94
CBQ11 0.64 0.94
CBQ12 0.78 0.94
CBQ13 0.79 0.94
CBQ14 0.59 0.94
CBQ15 0.49 0.94
CBQ16 0.75 0.94
CBQ17 0.69 0.94
CBQ18 0.60 0.94
CBQ19 0.48 0.94
CBQ20 0.68 0.94significantly higher than healthy comparison group (21.6
±4.6, p<0.001).
Reliability for BSU
Internal consistency
Internal consistency: In order to determine the instru-
ment’s internal consistency reliability, the Cronbach
alpha coefficient was calculated. Its reliability was .93.
The internal consistency of BSU subscales was .91 for
subscale 1: facilitative beliefs about heroin use, .88 for
subscale 2: psychophysical beliefs about heroin use.For
subscale 1, intraclass correlation coefficient (ICC) was
used to determine the inter-rater reliability coefficient. It
showed that there is strong reliability based on the 95%
confident interval of the ICC estimate (ICC = 0.909, N =
295, P <0.001). For subscale 2, intraclass correlation co-
efficient (ICC) was used to determine the inter-rater reli-
ability coefficient. It showed there is strong reliability
based on the 95% confident interval of the ICC estimate
(ICC = 0.867, N = 295, P <0.001).
Item discrimination: For BSU, the item discrimination
indices ranged from .37 to .77. The corrected item-total
correlations have shown that each of the items of BSU
revealed good reliability (Table 4). The assessment of
similar test validity has shown a positive correlation be-
tween CBQ–BSU scores (pc: 0.59, p < 0.001). No correla-
tions were found between total and subscale scores of
API and total scores of BSU (pc: 0.12, p = 0.1).
Interplay of substance related cognitions with mood,
anxiety and other triggering factors
Patient group showed significantly higher CBQ, BSU,
BAI and BDI scores, compared to healthy comparison
group (p < 0.001, t-test). Based on the pearson correl-
ation test, both CBQ and BSU scores significantly corre-
lated with BAI scores (Pc:0.27, p < 0.001 and Pc: 0.38,
p < 0.001, respectively) and BDI scores (Pc:0.31, p < 0.001
and Pc: 0.43, p < 0.001, respectively). CBQ and BSU scores
correlated with API total scores (Pc: 0.24, p = 0.001 and
Pc: 0.24, p = 0.001, respectively) and API craving scores
(Pc:0.25, p = 0.001 and Pc: 0.26, p < 0.001, respectively).
Correlation of BSU and CBQ scores with addiction profile
Based on the pearson correlation test, BSU score signifi-
cantly correlated with API-substance use profile score
(Pc: 0.29, p < 0.001), API-diagnosis (Pc: 0.21, p < 0.001)
and CBQ (Pc: 0.23, p = 0.002). API-substance use profile
score corresponds to higher number and frequency of
different substances. API-diagnosis score corresponds to
higher number of problems related to substance use.
CBQ scores significantly correlated with API-impact
on life (Pc: 0.29, p < 0.001), API craving (Pc: 0.50, p <
0.0001), API- total score (Pc: 0.25, p = 0.001), BSU (Pc:
0.23, p = 0.002), and negatively correlated with the
Table 3 Items and Factor Loadings of BSU
Item Factor loading
Factor 1: Facilitative beliefs about heroin use
BSU10 I don’t deserve to recover from use/drink 0.91
BSU11 I’m not a strong enough person to stop 0.84
BSU13 Drug use and drinking are not problems for me 0.84
BSU16 If someone has a problem with drugs/drink, it’s all genetic 0.79
BSU9 Life would be depressing, if I stopped 0.78
BSU7 My life won’t get any better, even if stop using drugs/drinking 0.69
BSU4 This is the only way to cope with pain in my life 0.69
BSU2 Using drugs is the only way to increase my creativity and productivity 0.69
BSU12 I could not be social without using drugs/drinking 0.59
BSU17 I can’t relax without drugs/drinking. 0.39
Factor 2: Psychophysical beliefs about heroin use
BSU19 I can’t control my anxiety without using drugs/drinking. 0.89
BSU14 The cravings/ urges won’t go away unless I use drugs/drinking 0.80
BSU15 My drug use/drinking is caused by someone else (e.g. spouse, family, etc. 0.77
BSU6 The craving/urges make me use drugs/drinking 0.66
BSU20 I can’t make my life fun unless I use drugs/drinking 0.62
BSU1 Life without using drugs/drinking is boring. 0.61
BSU8 The only way to deal with my anger is by using drugs/drinking 0.57
BSU18 Having this drug/drink problem means I am fundamentally a bad person 0.56
BSU3 I can’t function without it. 0.47
BSU5 I am not ready to stop using drugs/drinking. 0.40
Variance 54.5%
Component Number
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Fig. 2 Scree plot for BSU
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Table 4 Item-total correlation and Cronbach’s alpha if item
deleted
BSU Item-total correlation Cronbach’s Alpha if item deleted
BSU1 0.62 0.93
BSU 2 0.76 0.93
BSU 3 0.73 0.93
BSU 4 0.77 0.93
BSU 5 0.62 0.93
BSU 6 0.56 0.93
BSU 7 0.69 0.93
BSU 8 0.62 0.93
BSU 9 0.73 0.93
BSU 10 0.58 0.93
BSU 11 0.64 0.93
BSU 12 0.53 0.93
BSU 13 0.62 0.93
BSU 14 0.53 0.93
BSU 15 0.36 0.94
BSU 16 0.65 0.93
BSU 17 0.67 0.93
BSU 18 0.54 0.93
BSU 19 0.62 0.93
BSU 20 0.73 0.93
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API-impact on life mainly corresponds to social prob-
lems and dysfunctions caused by substances.
Number of previous treatment attempts to stop using
substances, age of substance use onset and duration of
substance use were not correlated either BSU or CBQ
(p > 0.1).
Regardless of the substance they used in addition to
heroin, patients with any substance use in the last month
significantly reported higher CBQ scores, (77.4 ± 20 vs 53
± 25 respectively, p < 0.001), but no difference in BSU
scores (51 ± 25 vs 58 ± 24.5 respectively, p = 0.08). Patients
reporting heroin as the substance they used for the longest
time, had lower mean CBQ scores compared to others
(60.5 ± 26.5 vs 70 ± 23.4 respectively, p = 0.016).
A multivariate linear regression model was fit with
covariates: age, gender, educational status, income level,
amount of smoking, beck depression and beck anxiety
scale scores to test if they could predict CBQ or BSU
scores. Both models showed a significant effect of the vari-
ables (r2: 0.34, p < 0.001 for CBQ and r2: 0.27, p < 0.001
for BSU), however sociodemographic variables had an
insignificant effect, whereas CBQ scores were significantly
predicted by the amount of smoking (B coefficient: − 0.43,
p < 0.001) and beck depression scores (B coefficient:0.25,
p = 0.006). BSU scores were predicted by both the amountof smoking (B coefficient:0.20, p = 0.001), beck anxiety
scores (B coefficient:0.25, p < 0.001) and beck depression
scores (B coefficient:0.30, p < 0.001).
Discussion
The findings in the present study indicate that the
Turkish versions of BSU and CBQ are useful tools to
evaluate the beliefs of patients with heroin use disorder
about heroin use and cravings. Both scales showed
significant discriminative validity and internal consistency
reliability. These findings support that for all subgroup
analysis, both BSU and CBQ are able to distinguish
patients with heroin use disorder significantly from
healthy comparison group. The assessment of similar test
validity has shown a positive correlation between CBQ–
BSU scores.
The analysis of CBQ showed that craving beliefs for
drugs are grouped around two factors. First factor, which
is named as ‘Psychophysical reactions to Craving’ in this
study, mainly seems related with the effects of craving on
daily life, mental health and physical health. Second factor,
which is named in this study as ‘Weakness to cope with
craving’ in this study, mainly involves negative thoughts
about self-resources to cope with craving. According to
our findings of BSU, these maladaptive beliefs could also
be examined in two main factors. First factor, which is
named in this study as ‘facilitative beliefs about heroin
use’, mainly, involves items about self-worthlessness, lack
of insight for substance use problem and negative
thoughts about self-resources to cope with the substance.
Second factor, which is named in this study as ‘psycho-
physical beliefs about heroin use’, involves items about the
role of substance in novelty creating in life, in addition to
lack of insight for substance use problem. In current
study, higher frequency and variety of substance use are
also positively related with these beliefs in the analysis of
API substance use dimension. These subscales of both
scales could be used in further studies for understanding
their relationship with treatment adherence, number of
relapses and duration of abstinence. Also they could be
used as distinct dimensions to focus on therapy sessions
for increasing meta-cognitive awareness and challenging
maladaptive thoughts as suggested in trans diagnostic
CBT for SUD and depression [32].
Our data suggests that the more patients with heroin
use disorder had craving beliefs, the more they had
depressive symptoms, anxiety and social problems in
daily life. It supports the study that emphasized the qual-
ity of life was worse among patients with heroin use dis-
order who had psychiatric comorbidities such as anxiety
or depression [33]. The risk of comorbidity of substance
use disorders with depressive episodes are reported as
almost 3 fold increased and it is also associated with a
worse outcome for both disorders [32]. Maladaptive and
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SUD and depressive episodes.
Depressed individuals report more negative beliefs and
less metacognitive awareness [34]. Affective states also
are significant modulators for decision-making processes
of substance use disorders and this relationship is also
bound to the duration of substance use [35]. Patients
with a substance use may also present with severe
impulse control disorders that are objectively measured
by tasks as Iowa gambling test [36]. Our study points
out that it is insufficient to focus only on substance use
in addiction treatment, because craving for heroin may
significantly be associated with impaired decision mak-
ing, having negative mood/anxiety states and impulsive
behaviors which may need a holistic approach in treat-
ment. These thought patterns were shown to explain
some of the relationship between depression and coping
behaviors against alcohol use for adolescents [37] in
accordance with our findings. This finding is often stated
for patients with alcohol use disorder [38], however its
study in patients with heroin use disorder is limited.
Anxiety and depression are significant modulators for
patients’ beliefs about substance use and depression is a
modulator for craving, validating emotion-cognition
interplay in addiction.
Another significant finding of this study was the rela-
tionship between tobacco use and heroin craving. CBQ
scores were lower in patients with heroin use disorder
who reported higher amounts of smoking. And there
was a moderate correlation among these variables.
Smoking may be a gate-away pathway to decrease heroin
use, however it is also argued in literature that concomi-
tant tobacco and heroin use seems to increase craving
[39]. Tobacco smoking is often ignored in substance
dependence treatment, and further attention and investi-
gation on their association is needed.
It may be argued here that BDI is not an adequate
psychometric tool to detect depressive symptoms in
patients with heroin use disorder and that BDI scores in
this study may not be the correspondence of a depres-
sive episode, however BDI is a valid tool for assessment
in this group [40]. The positive correlation between
BAI-BDI and BSU-CBQ scores could reveal that the
belief about providing a positive relief after substance
use has a positive relationship with anxiety level and
higher depressive automatic thoughts.
Lastly, this study has some limitations. Depressive
symptoms, anxiety symptoms, craving and maladaptive
beliefs were assessed through self-reports. The biological
verifications would provide effectively assessment of the
vicious cycle in heroin addiction. The study was
cross-sectional and it does not allow us to assess the
causality and relationship between depressive symptoms,
anxiety symptoms, craving and substance related beliefs.Also, participants have not been tested for test retest re-
liability. Future study could assess participants at mul-
tiple time points to detect the changes in substance use,
mental health, craving and substance related beliefs. The
design of the study does not allow whether or not
gender differences and treatment options affect craving
and substance related beliefs in heroin addiction. Effects
of personal traits and other mental health related issues
could be assessed in future studies.
Conclusion
In conclusion, Turkish version of BSU and CBQ are
useful tools to detect maladaptive beliefs in patients with
heroin use disorder. Subscales of BSU and CBQ should
be taken into account in future studies. Depressive
symptoms and anxiety are more prevalent in patients
with heroin use disorder than comparison group and
they correlate with distorted beliefs that maintain
substance use. Due to this relationship, depressive symp-
toms and anxiety should be also the targets in treatment
of patients with heroin use disorder. Patients’ maladap-
tive beliefs affect the course of illness and smoking may
modulate these beliefs. These findings validate
emotion-cognition interplay in addiction. Duration of
substance use disorders is less effective compared to
maladaptive beliefs on the severity and course of the dis-
order. Future studies targeting maladaptive thoughts
specifically should be conducted.
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